You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 144 No. 1, January 2008 TABLE OF CONTENTS
  Archives
  •  Online Features
  Editorial
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Drug Therapy, Other
 •Immunologic Disorders
 •Immunology, Other
 •Prognosis/ Outcomes
 •Bullous Diseases
 •Pemphigus
 •Drug Therapy
 •Alert me on articles by topic

Treatment of Pemphigus

The Need for More Evidence

Linda K. Martin, BA, BSc(Med), MBBS, MMed(ClinEpi); Dedee F. Murrell, MA, BM BCh, FAAD, MD

Arch Dermatol. 2008;144(1):100-101.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Pemphigus vulgaris is a prototype antibody-mediated autoimmune disorder in which autoantibodies against desmosomal intraepidermal adhesion proteins lead to acantholysis and blister formation. Although our understanding of the molecular pathogenesis of pemphigus and other autoimmune bullous diseases has increased markedly in recent decades, similar progress regarding effective treatment has not been made.

There are a large number of potential interventions for pemphigus.1 The cornerstone of treatment is corticosteroids, although use of immunosuppressive agents, immunomodulatory agents, plasmapheresis, intravenous immunoglobulin, and biological agents has also been described. The efficacy and role of each of these agents has not been established.

The advent of synthetic glucocorticosteroids in the 1950s revolutionized the treatment and prognosis of pemphigus, with mortality rates improving from 90% to 10%. Unfortunately, in the ensuing 5 decades, there has been little advancement in treatment, and the . . . [Full Text of this Article]


AUTHOR INFORMATION

RELATED ARTICLE

Multicenter Randomized, Double-blind, Placebo-Controlled, Clinical Trial of Dapsone as a Glucocorticoid-Sparing Agent in Maintenance-Phase Pemphigus Vulgaris
Victoria P. Werth, David Fivenson, Amit G. Pandya, Diana Chen, M. Joyce Rico, Joerg Albrecht, and David Jacobus
Arch Dermatol. 2008;144(1):25-32.
ABSTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Dapsone: Is It Useful in Pemphigus?
Journal Watch Dermatology 2008;2008:3-3.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2008 American Medical Association. All Rights Reserved.